A detailed history of High Tower Advisors, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, High Tower Advisors, LLC holds 29,372 shares of NBIX stock, worth $3.64 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
29,372
Previous 15,938 84.29%
Holding current value
$3.64 Million
Previous $2.2 Million 83.94%
% of portfolio
0.01%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$130.86 - $143.19 $1.76 Million - $1.92 Million
13,434 Added 84.29%
29,372 $4.04 Million
Q1 2024

May 06, 2024

BUY
$130.4 - $143.74 $72,502 - $79,919
556 Added 3.61%
15,938 $2.2 Million
Q4 2023

Feb 12, 2024

BUY
$106.07 - $132.76 $864,364 - $1.08 Million
8,149 Added 112.66%
15,382 $2.03 Million
Q3 2023

Nov 08, 2023

BUY
$94.02 - $117.1 $58,762 - $73,187
625 Added 9.46%
7,233 $813,000
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $116,120 - $136,016
-1,297 Reduced 16.41%
6,608 $623,000
Q1 2023

May 11, 2023

SELL
$94.11 - $123.02 $35,855 - $46,870
-381 Reduced 4.6%
7,905 $800,000
Q4 2022

Feb 08, 2023

BUY
$106.72 - $127.06 $272,136 - $324,003
2,550 Added 44.46%
8,286 $989,000
Q3 2022

Nov 09, 2022

SELL
$92.03 - $107.81 $5,245 - $6,145
-57 Reduced 0.98%
5,736 $607,000
Q2 2022

Aug 10, 2022

BUY
$75.79 - $100.07 $3,637 - $4,803
48 Added 0.84%
5,793 $566,000
Q1 2022

May 12, 2022

BUY
$72.45 - $94.81 $136,423 - $178,527
1,883 Added 48.76%
5,745 $544,000
Q4 2021

Feb 10, 2022

SELL
$79.65 - $106.22 $170,610 - $227,523
-2,142 Reduced 35.68%
3,862 $332,000
Q3 2021

Nov 12, 2021

SELL
$86.18 - $99.03 $2.27 Million - $2.61 Million
-26,344 Reduced 81.44%
6,004 $581,000
Q2 2021

Aug 06, 2021

BUY
$89.43 - $102.27 $2.36 Million - $2.7 Million
26,406 Added 444.4%
32,348 $3.15 Million
Q1 2021

May 10, 2021

BUY
$87.57 - $119.4 $19,615 - $26,745
224 Added 3.92%
5,942 $574,000
Q4 2020

Feb 10, 2021

SELL
$86.91 - $108.33 $214,233 - $267,033
-2,465 Reduced 30.12%
5,718 $551,000
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $349,156 - $490,729
3,631 Added 79.77%
8,183 $789,000
Q2 2020

Aug 10, 2020

SELL
$85.09 - $130.36 $11,146 - $17,077
-131 Reduced 2.8%
4,552 $555,000
Q1 2020

May 21, 2020

SELL
$75.11 - $113.76 $20,054 - $30,373
-267 Reduced 5.39%
4,683 $405,000
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $25,692 - $35,096
296 Added 6.36%
4,950 $532,000
Q3 2019

Nov 12, 2019

SELL
$83.82 - $101.5 $2,849 - $3,451
-34 Reduced 0.73%
4,654 $419,000
Q2 2019

Aug 13, 2019

BUY
$72.24 - $91.27 $16,326 - $20,627
226 Added 5.06%
4,688 $396,000
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $24,674 - $32,584
356 Added 8.67%
4,462 $393,000
Q4 2018

Feb 14, 2019

SELL
$68.32 - $124.36 $1,503 - $2,735
-22 Reduced 0.53%
4,106 $293,000
Q3 2018

Nov 09, 2018

BUY
$98.88 - $125.85 $2,175 - $2,768
22 Added 0.54%
4,128 $508,000
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $527 - $741
-7 Reduced 0.17%
4,106 $404,000
Q1 2018

May 15, 2018

BUY
$75.88 - $92.43 $99,175 - $120,806
1,307 Added 46.58%
4,113 $342,000
Q4 2017

Feb 14, 2018

BUY
$58.53 - $77.59 $164,235 - $217,717
2,806
2,806 $218,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.